TY - JOUR T1 - Assessment & mitigation of O2 therapy driven spread of COVID-19 JF - medRxiv DO - 10.1101/2021.02.06.21251266 SP - 2021.02.06.21251266 AU - Arshad Kudrolli AU - Brian Chang AU - Jade Consalvi AU - Anton Deti AU - Christopher Frechette AU - Helen Scoville AU - Geoffrey R. Sheinfeld AU - William T. McGee Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/02/08/2021.02.06.21251266.abstract N2 - BACKGROUND Exhalation exposure from patients to healthcare workers (HCWs), while using a nasal cannula or simple O2 mask used in treating COVID-19 and other respiratory diseases, is a present and future risk. Little is known on exhalation dispersal through these devices, and on mitigating the viral exposure to those in the vicinity.METHODS Respiration through O2 therapy devices was studied with a supine manikin equipped with a controllable mechanical lung by measuring aerosol density and flow with direct imaging. Dispersal direction and distances were quantified while placing a surgical mask loosely over the devices and contrasted with unmitigated oxygenation device use. Exhalation jets were examined over the entire range of oxygenation rates used in treatment.RESULTS Exhalation jets travel 0.35 ± 0.02 m upward while wearing a nasal cannula, and 0.29 ± 0.02 m laterally while wearing a simple O2 mask posing significant inhalation risk. Placing a surgical facemask loosely over the oxygenation device is demonstrated to alleviate exposure by reducing and deflecting the exhalation jets from being launched forward, and by reducing exhalations from being launched directly higher over a supine patient. Less than 12% of the exhaled breath is observed to reach above a masked face where HCWs would be present, independent of oxygen flow rates.CONCLUSIONS Exhalation jets from both the nasal cannula or simple O2 mask were found to concentrate aerosol-laden exhalations directly in front of a patient’s face. Exposure is effectively mitigated with a surgical mask which reduces and redirects the exhalation downward away from HCWs.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by U.S. National Science Foundation COVID-19 RAPID Grant No. DMR-2030307.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:None required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is contained in the manuscript. http://physics.clarku.edu/~akudrolli/covid ER -